Long-Term Impact of Ivacaftor on Healthcare Resource Utilization Among People with Cystic Fibrosis in the United States

INTRODUCTION: Ivacaftor was first approved in 2012 for the treatment of a select population of individuals with cystic fibrosis (CF), a rare, life-shortening genetic disease. Reductions in healthcare resource utilization (HCRU) associated with ivacaftor have been observed during limited follow-up an...

Descripción completa

Detalles Bibliográficos
Autores principales: Thorat, Teja, McGarry, Lisa J., Jariwala-Parikh, Krutika, Limone, Brendan, Bonafede, Machaon, Chandarana, Keval, Konstan, Michael W.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2021
Materias:
Brief Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8137794/
https://www.ncbi.nlm.nih.gov/pubmed/33913076
http://dx.doi.org/10.1007/s41030-021-00154-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8137794/
https://www.ncbi.nlm.nih.gov/pubmed/33913076
http://dx.doi.org/10.1007/s41030-021-00154-9

Ejemplares similares